Obstet Gynecol Sci > Volume 65(6); 2022 > Article |
|
Ethical approval
This study was approved by the Human Ethics Committee of the Faculty of Medicine, Prince of Songkla University.
Value (n=364) | Complicationa) | P-value | ||
---|---|---|---|---|
No (n=336) | Yes (n=28) | |||
Age (yr) | 60 (50-87) | 59.7 (7.1) | 62 (7.2) | 0.017 |
Body mass index (kg/m2) | 27.2 (13.0-8.5) | <0.001 | ||
≤23 | 73 (21.7) | 3 (10.7) | ||
23-24.9 | 58 (17.3) | 3 (10.7) | ||
25-29.9 | 130 (38.7) | 5 (17.9) | ||
≥30 | 75 (22.3) | 17 (60.7) | ||
Comorbidities | 0.001 | |||
Yes | 244 (67.0) | 217 (64.6) | 27 (96.4) | |
No | 120 (33.0) | 119 (35.4) | 1 (3.6) | |
Performance status (ECOG) | 0.337 | |||
0 | 57 (15.7) | 54 (16.1) | 3 (10.7) | |
1 | 302 (83.0) | 278 (82.7) | 24 (85.7) | |
2 | 5 (1.4) | 4 (1.2) | 1 (3.6) | |
ASA class | <0.001 | |||
1 | 65 (17.9) | 65 (19.3) | 0 (0.0) | |
2 | 248 (68.1) | 234 (69.6) | 14 (50.0) | |
3 | 51 (14.0) | 37 (11.0) | 14 (50.0) | |
mFI score | <0.001 | |||
0 | 155 (42.6) | 153 (45.5) | 2 (7.1) | |
1 | 125 (34.3) | 114 (33.9) | 11 (39.3) | |
2 | 74 (20.3) | 65 (19.3) | 9 (32.1) | |
≥3 | 10 (2.7) | 4 (1.2) | 6 (21.4) | |
Hemoglobin (mg/dL) | 12.2±1.4 | 12.2±1.4 | 12.1±1.6 | 0.85 |
Platelet count (/μL) | 300,870±84,977.7 | 297,426±79,342.9 | 241,821±130,340.3 | 0.008 |
Serum albumin (g/dL) | 4.3±0.4 | 4.4±0.3 | 4.1±0.6 | <0.001 |
Serum creatinine (mg/dL) | 0.7±0.2 | 0.7±0.2 | 0.8±0.2 | 0.461 |
Pathology | 0.005 | |||
Endometrioid | 299 (82.1) | 282 (83.9) | 17 (60.7) | |
Non-endometrioid | 65 (17.9) | 54 (16.1) | 11 (39.3) | |
Stage of disease | 0.018 | |||
I | 255 (70.1) | 239 (71.1) | 16 (57.1) | |
II | 24 (6.6) | 18 (5.4) | 6 (21.4) | |
IIIA, B | 19 (5.2) | 17 (5.1) | 2 (7.1) | |
IIIC1, C2 | 51 (14.0) | 49 (14.6) | 2 (7.1) | |
IV | 15 (4.1) | 13 (3.9) | 2 (7.1) | |
Adjuvant treatment | 214 (58.8) | 0.428 | ||
Radiotherapy alone | 122 (57.0) | 115 (58.1) | 7 (43.8) | |
Chemotherapy alone | 54 (25.2) | 48 (24.2) | 6 (37.5) | |
Combined therapy | 38 (17.8) | 35 (17.7) | 3 (18.7) | |
30-day hospital readmission | <0.001 | |||
Yes | 14 (3.8) | 6 (1.8) | 8 (28.6) | |
No | 350 (96.2) | 330 (98.2) | 20 (71.4) |
Score | Complicationa) rate (%) | Odds ratio (95% CI) |
---|---|---|
0 | 1.3 | Reference |
1 | 8.8 | 7.38 (1.6-33.95) |
2 | 12.2 | 10.59 (2.23-50.38) |
≥3 | 60.0 | 114.75 (17.45-754.42) |
Variable | Odds ratio (95% CI) | P-value |
---|---|---|
Age (yr) | 0.009 | |
<60 | 1 | |
≥60 | 2.92 (1.25-6.81) | |
Body mass index (kg/m2) | <0.001 | |
≤23 | 1 | |
23-24.9 | 1.26 (0.24-6.47) | |
25-29.9 | 0.94 (0.22-4.03) | |
≥30 | 5.52 (1.55-19.62) | |
Performance status (ECOG) | 0.516 | |
0 | 1 | |
1 | 1.55 (0.45-5.34) | |
2 | 4.50 (0.38-53.77) | |
ASA class | <0.001 | |
≤2 | 1 | |
3 | 8.08 (3.57-18.27) | |
mFI score | <0.001 | |
0 | 1 | |
1 | 7.38 (1.6-33.95) | |
2 | 10.59 (1.5-11.5) | |
≥3 | 114.75 (17.45-754.42) | |
Serum albumin (g/dL) | 0.26b) (0.11-0.6) | 0.002 |
Serum creatinine (mg/dL) | 2.23b) (0.27-18.7) | 0.47 |
Pathology | 0.005 | |
Endometrioid | 1 | |
Non-endometrioid | 3.38 (1.50-7.61) | |
Stage of disease | 0.051 | |
I | 1 | |
II | 4.98 (1.74-14.28) | |
IIIA, B | 1.76 (0.37-8.28) | |
IIIC1, C2 | 0.61 (0.14-2.74) | |
IV | 2.3 (0.4811.07) |
Studies of free radical scavenger enzymes in RBC from cervical cancer patients.1991 June;34(6)
Clinicopathological correlation in endometrial carcinoma.1992 April;35(4)